Ahmedabad, 16th June, 2021: ART Fertility Clinics, a leading global institution in Reproductive Medicine, today launched its exclusive clinic in Ahmedabad, Gujarat at Sun Avenue, Manek Baug Road.  The center will provide highly specialized IVF treatment to patients from Ahmedabad and the areas.  ART Fertility Clinics launched its first two clinics in Gurgaon and Delhi in May 2021 and the Ahmedabad clinic is its first foray into western India.

 

ART Fertility Clinics follow the doctrine of evidence-based medicine and provide personalized treatment plans for all its patients. Treatment plans at ART Clinics are personalized on the basis of its proprietary research which takes into account ethnicity, social and cultural mores, previous medical history. This holistic approach of combining science, nature and geographical factors has enabled ART Fertility Clinics to achieve the highest successful pregnancy rates globally of 69%.  ART Fertility Clinics aims to transform IVF (In-vitro fertilization) technology sector in India by implementing the most stringent IVF protocols (ESHRE) across all its centers.

 

Speaking at the occasion of the launch, Mr. Vinesh Gadhia, CEO, ART Fertility Clinics India said, “ART Fertility Clinics, Ahmedabad is the most technologically advanced center for  reproductive medicine in the city.  The clinic provides finest infrastructure and the latest technology to ensure that our patients have the best environment for a successful pregnancy.  Ahmedabad center is our third clinic in the country and is a part of our India expansion plan.  ART Fertility Clinics is about science assisting nature and we aspire to be an essential bridge in helping couples attain their dream of parenthood.”

Launched in early 2015 in collaboration with IVI RMA Global, ART Fertility clinics is now an independent and leading provider of Fertility treatments with the highest success rates internationally (69% Pregnancy rate: 1.3 Embryos per transfer, no donor eggs or sperm).  The institution deploys the most advanced infrastructure and technologies in all its clinics, some of these technologies and equipment are being introduced in India for the very first time.  Having achieved over 60000 + pregnancies in less than five years, globally, ART Fertility Clinics’ success is driven by the scientific and personalized approach of highly skilled physicians, embryologists and the support medical team. With a focus on original research and publications, ART Fertility Clinics has become an international referral center for patients seeking advanced treatments especially after multiple failed cycles using their own eggs.

As a part of its India expansion plan, ART Fertility Clinics will be launching 15 more state-of-art centers over next two years across India.

About ART Fertility Clinics

ART Fertility Clinics was started as an extension IVI RMA Global in 2015 under the brand name IVI Middle East. In Jan 2020, IVI RMA divested its ownership to Gulf Capital and the entity was rechristened as ART Fertility Clinics. Since its inception, ART Fertility Clinics has been led by Mr. Suresh Soni, Chief Executive Officer and Prof. Dr. Human Fatemi, Group Medical Director (MD, Ph.D. at the University of Brussels, Belgium).

In the past six years, ART Fertility Clinics has established Clinics in Abu Dhabi, Muscat and Dubai and become the leading institute for Human Reproductive Medicine in the Middle East.

As part of the global expansion initiative mandated by Gulf Capital, ART Fertility has expanded its presence India, commencing operations in eight clinics across India in 2021 with an additional ten clinics to begin operations by Mid-2022. ART Fertility Clinics will be announcing the launch of several clinics in Europe and Asia during the second half of 2021.

May, 2021: India Pulses and Grains Association (IPGA), the nodal body for India’s pulses trade and industry, have recently donated one ventilator to the Shrimad Rajchandra Love and Care (SRLC) Hospital in Dharampur, Valsad District, Gujarat, in continuation of their CSR efforts to provide support and relief in rural India during the Covid-19 pandemic. IPGA has been working to strengthen the hands of the frontline workers by donating a ventilator to treat COVID patients especiallythe disadvantaged tribal people of South Gujarat under the Shrimad Rajchandra Love and Care program. This is an initiative for and beyond COVID to serve the people in rural areas for years to come.

The SRLC hospital, a 100-bedded facility in Dharampur town of Valsad district, is the only equipped and multi-specialty hospital amidst 100 villages in the area. As the second wave of Covid-19 began spreading rapidly in southern Gujarat, SRLC immediately converted one wing into a 50-bedded Covid-19 special ward equipped with ICU and BiPAP machinery, high-flow oxygen support and an experienced team of doctors and started treating patients from the under privileged tribal communities in rural areas free of cost. IPGA responded to these efforts by donating a ventilator to their ICU for treating critical Covid-19 patients.

Mr. Jitu Bheda, Chairman – IPGA said, “IPGA is honoured to support a noble cause of providing quality and critical healthcare to the less privileged citizens of Gujarat and step up the fight against COVID-19. As the nodal body of the pulses trade, we are proud of all the CSR work done so far. We will always step up to support all the state and central government efforts in this time of crisis. This ventilator will be useful for years to come beyond COVID. We hope that our effort encourages other similar Associations to come forward and contribute.”

Speaking about IPGA’s support, Dr Bijal Mehta, Trustee, SRLC Hospital, said, “The ventilator has been installed in the Critical ICU Ward installed at our hospital last week and is working well. IPGA’s donation was very timely and has helped us to extend much needed Covid care to underprivileged patients. We are very grateful to IPGA for joining hands with us to serve the less fortunate, and I thank IPGA on behalf of the hospital and all the Covid-19 patients.”

Since the Covid-19 pandemic hit India last year, IPGA has decided to dedicate certain resources to fighting the pandemic and supporting frontline workers as well as victims through it. Last year, IPGA contributed a sum of INR 21 lakhs to the PM-CARES fund, as well as provided 11,000 food grain ration bags to migrant families and families stuck in containment zones.

May : Maruti Suzuki India Limited in partnership with Zydus Hospitals announces the start of a multi-speciality hospital at Sitapur in Ahmedabad District of Gujarat. With a total capital expenditure of Rs 126 crores, the hospital has been 100% funded by the Maruti Suzuki Foundation – a CSR initiative of Maruti Suzuki. The hospital will be managed and operated by Ramanbhai Foundation, the CSR arm of Zydus Group.The hospital is also assisting in taking care of Covid-19 patients and strengtheningthefight against the pandemic.

Maruti Suzuki starts a multi-speciality hospital at Sitapur, Gujarat in partnership with Zydus Hospitals 2

Mr Kenichi Ayukawa, MD and CEO, Maruti Suzuki India said, “When our Gujarat car plant started, there was no major medical facility available in the region. We decided to build a good quality multi-speciality hospital for the benefit of all residents of that area and partnered with one of the best names in healthcare – Zydus Hospitals. Fortunately, it was in time for the Covid-19 second wave and we have converted it into a Covid-care facilityto help fight the pandemic. We would like to express our gratitude to the Government of Gujarat and the Government authorities of Ahmedabad District for their support in this project.”

The hospital is expected to serve over 3.75 lakh people residing at Sitapur and adjoining villages at affordable charges. Starting with a 50-bed facility, the hospital can be progressively expanded to 100 bedsbasis the demand. The infrastructure is already in-place for the expansion of the facility.The facility is spread over 7.5 acres and isthe first onMD and CEO, e in the area with super specialization services.

 

Salient features of the hospital include:

India,2021:FMC India today announced its commitment towards COVID-19 relief measures in India, which will focus on enhancing the oxygen supply at hospitals across five states, and running safety awareness campaigns in rural areas to curb the spread of the virus.

PramodThota, President of FMC India said, “Our entire nation is challenged by the severity and intensity of the second wave of COVID-19, causing multiple shortages of critical supplies due to an exponential demand for medical infrastructure. To help meet some of the urgent demand for oxygen at area hospitals, FMC India will contribute seven PSA plants to support urgent patient care and save precious lives. We are committed to partnering with our channel partners and communities to help address some of the critical healthcare shortages in India – particularly in the rural areas with high COVID-19 rates and fewer medical resources.”

Increasing Oxygen Supply

According to the Indian government, the demand for oxygen at hospitals and healthcare facilities has increased almost ten times compared to demand prior to the pandemic. With COVID-19 cases rising rapidly, many patients with severecoronavirus are not getting the emergency oxygen supply they need. In order to help fulfill the rapidly increasing requirement for medical oxygen, FMC India will procure and donate sevenPressure Swing Adsorption (PSA) oxygen plants to hospitals in Delhi NCR, Uttar Pradesh, Madhya Pradesh, Maharashtra, and Gujarat. The installationof PSA oxygen plants at these hospitals will enable a continued supply of oxygen, without the challengesof transportation logistics.

As the country battles a second critical wave of the pandemic, these initiatives will augment the supply near the underserved demand clusters, by producing 1,680Nm3of oxygen daily to support local hospitals, in the nation’s fight against COVID-19.

Rural Awareness Campaigns

The coronavirus is spreading significantly throughout rural India during this wave. FMC India will launch amulti-facetedcampaign aimed at educating local farmers and growers about safety and wellnessmeasures to protect themselves from COVID-19, while continuing farming and adopting good agricultural practices. The awareness campaigns are expected to reach around 100,000 farmers across various leading agricultural states in India. All these efforts are part of FMC India’s ongoing community empowerment initiative – Project Samarth

March 2021: As part of its awareness initiative, the Hemophilia Federation (India) has organized a west region online summit, powered by Takeda Pharmaceutical Company. The summit is a step to connect and reach out to the larger community involving, people with hemophilia, physicians, doctors and policy makers.

The western region Hemophilia Management Summit was opened with, Mr. MukeshGarodia, President, HFI, welcoming everyone and giving a backgrounder of the current state of hemophilia in this part of the country.

Mr. Garodia, said, “These summits very accurately present the communities need and encourage perspectives which helps in generating innovative ideas and open new opportunities. HFI’s goal is establishment of comprehensive hemophilia care center in every state and the most important aspects of hemophilia management are prophylaxis and home therapy for all hemophiliacs.This is our vision to achieve by 2025.”

The web summit concentrated on inhibitor management. Inhibitor is one of the most important complication in management of hemophilia. Over the years the contribution from the state governments has increased in procurement of Factors.

Product Procurement at State Level was one of the most important panel discussion moderated by Dr. Chandrakala (KEM Hospital) and Dr. Vijay B Shah, Government Medical College, Surat; Dr. MahendraKendre, National Health Mission, Maharashtra; Mr. R.K Nigam, Gandhi Medical College, Bhopal; and Dr. VarshaMunj, Asilo Hospital Mapusa, Goa on the panel.

According to a global survey, there are an approx. 20,000 hemophilia patients in India, amongst them as per the available data there are only 4% inhibitors in this, but we suspect it is more than that. The west zone is 2nd largest when it comes to inhibitor positivity with 13.8% and the south zone ranked highest with 19.35% and north stands on the 3rd spot with 10.85% inhibitor positivity.

Multiple knowledge sessions were carried out during the summit, like, Monitoring of Inhibitor in routine practice by Dr. Shrimati Shetty; Management of patients with inhibitor by Dr. Joseph John; and Management of Rare Bleeding Disorder by Dr. Sanjeevan Sharma.

On the closing of the summit, Ms. Nilovna Ghosh, from Takeda shared, “We have a long standing partnership with HFI that we greatly value at Takeda, as we pay a lot of impetus on collaborative initiatives that we have ongoing and upcoming. We are a highly patient centric global company, and in the space of Hemophilia we have been working on bringing innovation.”

The next summits are to be held on 20th east region and 27th March 2021, south region. To follow the upcoming summits, please follow the HFI on https://www.facebook.com/profile.php?id=100011851031233

March, 2021 : Mindray a leading medical device company and as a – ‘Trusted Partner for Healthier Bharat’ is glad to collaborate with United Green Hospital, Surat in inaugurating first Mindray Standardized Laboratory in India.

The company has established itself as a valuable and a goal-driven global leader in medical technology both as a manufacturer and a marketer of medical devices. Mindray India has been constantly engineering to provide innovative, high-quality, feature-rich medical products for the Indian healthcare industry.

Therefore, moving further on the path of quality and commitment, Mindray has come up with a solution to serve customers better by Standardizing the Laboratory Practices to ensure optimum efficiency. Standardization of laboratory measurements is key to providing accurate and reliable results.

Standardised Laboratory: Everything You Need to Know:

A Standardised Laboratory uses advanced technology and follows standard protocols laid by the regulatory bodies [NABL & NABH]. Managed by a highly skilled team, Lab can offer a spectrum of test services in a sterilized environment. The infrastructure too plays a great role in managing a standardised laboratory. A lab with efficient design can control the unrestricted patient flow in a limited space. The disciplined use of the interiors can protect the visitors and patients from the risk of infections and undesired exposure.

Surat’s United Green Hospital Pathology Laboratory is the first Mindray Standardized Laboratory in India:

Mr. Sudeep Mukherjee, Deputy Director – IVD: Mindray Medical India Pvt. Ltd.-elaborated on their newest venture. According to Mr. Mukherjee the laboratory is an effort to provide expeditious and affordable diagnosis, monitoring, and treatment to the masses. He further added that Mindray being a trusted partner in building a healthier Bharat, aims to standardise workflow of such laboratories so as they can provide better patient care and improved clinical output. Standardizing entire laboratory operations will prove instrumental in detecting, treating, and preventing the spread of novel coronavirus in the public.

He also added that with the use of Mindray’s complete set of equipment and traceability system, and implementation in accordance with standards by laboratory at United Green Hospital will ensures reliable results and ultimately provides better services to patients

The modernised laboratory is designed and developed adhering to the international standards of diagnosis and management. It aims to provide high-quality diagnosis to clinicians for research and development. Armed with space-saving, advanced, sterilized, portable equipment, the laboratory is committed to safeguarding human health during and after the testing procedures.

Mindray’s complete set of IVD equipment’s and traceability system, which are installed in accordance with international standards, our laboratory ensures reliable results and ultimately provides better services to patients. With the help of standardization our laboratory has improved quality and efficiency and reduced redundancy and possibility of manual errors.

Dr. Haresh Vastarpara, MD of United Green Hospital, Surat elaborated on the growing need of sophisticated yet affordable diagnostic facilities for the masses. He emphasized that diagnosis is the most important step in the entire procedure of treatment. It played a vital part in combating the Covid-19 pestilence. He further added that the laboratory is completely capable of testing the Covid19 virus too. Laboratory is now upgraded with the help of Mindray India to international standards and optimized in all aspects, right from sample collection to processing to reporting. SOP’s are now laid out at every single step involving sample handling and analysis, instrumentation and its maintenance, documentation, workflow management and quality control aspects. With the help of standardization provided by Mindray India, we can bring in latest diagnostics procedures and adhere to best laboratory practices, which in turn helps our lab staff to focus more on our patients and improve diagnostics efficiency.